Mentor Capital (MNTR) Invests in Cancer Immunotherapy Index Companies

Mentor Capital, Inc. invests across all Companies in its proprietary Mentor Capital Cancer Immunotherapy Index that it formed July 10, 2009. The index detail and numerics may be viewed by clicking on the CI Index icon to the right.

Mentor Capital plans to apply the approximate $140 Million that may be collected as proceeds from its already authorized public financing tranches to the CI Index.  By strongly overweighting investments through its Cancer Immunotherapy Index Fund  into those index companies that show the greatest medical promise, Mentor Capital aims to improve on the return it earns in what appears to be an already quickly growing medical sector.